ABSTRACT
Objective To evaluate the clinical effect of Wuwei-Xiaodu decoction lavage assisted VSD in the treatment of perianal abscess pus period. Methods Ninety patients with perianal abscess who met the inclusion criteria were divided into 2 groups by random number table, 45 in each group. The control group was treated with 0.9％ sodium chloride injection assisted VSD. The treatment group was treated with Wuwei-Xiaodu decoction lavage assisted VSD treatment. Both groups were treated for 7 days. WBC was detected by automatic hemorheology tester, CRP, IL-6 and TNF-α were detected by ELISA. The anus bulge, anal self-made function, wound exudation, wound pain were scored and the incision bacteria were detected after treatment. The rate and number of colonies were evaluated. Results The total effective rate was 88.89％ (40/45) in the treatment group and 73.33％ (33/45) in the control group. The total effective rate of the two groups was statistically significant (Z=-2.584, P=0.010). After treatment, the levels of WBC, CRP, IL-6, and TNF-α in the treatment group were significantly lower than those in the control group (t=-3.730, -2.385, -2.170, -3.509, P=0.007, 0.023, 0.034, 0.011). The anal bulge, wound exudation, and wound pain scores in the treatment group were significantly lower than those in the control group (t=-2.760, -2.549, -21.151, P=0.005, 0.017, 0.038),. The rate of incision bacteria was significantly lower than that in the control group (χ2=4.406, P=0.036), the number of colonies were significantly lower than that of the control group (t=5.375, P<0.01). Conclusions The Wuwei-Xiaodu decoction lavage assisted VSD can effectively reduce the number of colonies in the perianal period of patients with perianal abscess, reduce postoperative anal bulge, pain and wound exudation, and improve clinical efficacy.
ABSTRACT
Objective To study the binding performance of 99Tcm labeled anti-human prostatic specific membrane antigen (PSMA) monoclonal antibody J591 (99Tcm-J591) and prostate cancer cells in vitro,the biodistribution and SPECT imaging of 99Tcm-J591 in nude mice bearing human prostate cancer in vivo.Methods The monoclonal antibody J591 was labeled with 99Tcm by improved Schwarz method.Labeled antibody was purified by Sephadex G-50.The labeling efficiency and radiochemical purity were measured by paper chromatography and trichloroacetic acid method.The binding performance of J591 and prostate cancer cells was measured by flow cytometry in vitro.The nude mice bearing PSMA-positive C4-2 prostate carcinoma xenografts served as experiment group,mice bearing PSMA-negative PC3 tumors served as control group.6.2-8.5 MBq of 99Tcm-J591 (25 μg) was intravenously injected into mice.Gamma imaging was performed 2,6,12 and 24 h after injection,T/NT was calculated by ROI technique.After scanned 12 h post injection,4 mice of the experiment group and 5 mice of the control group were sacrificed and the tracer in vivo biodistribution was measured by gamma-counting,and the ％ ID/g was calculated.Two-sample t test was carried out to validate significant difference of ％ID/g between two groups.Results The labeling efficiency and radiochemieal purity of 99Tcm-J591 were (78.9±6.2)％ and (92.3±5.1)％,respectively,and the specific activity of 99Tcm-J591 was 68.7 MBq/mg.The antibody J591 and 99Tcm-J591 could strongly combine with PSMA-positive C4-2 cells in vitro,and didn't combine with PSMA-negative PC3 cells in vitro.SPECT imaging results showed that radioactive concentration was obvious in tumor 6 h post injection,the concentration scope became large and the tumor image was clear 12 h post injection.T/NT was 1.9±1.1 at 2 h,4.3±1.8 at 6 h,5.6±2.7 at 12 h,1.4±0.6 at 24 h,respectively.In the control group,no radioactivity concentration was found in tumor,and T/NT was less than 2.The biodistribution results showed that ％ID/g of tumor tissue was 20.1±5.2 in the experiment group and 5.8±2.6 in the control group,and there was significant difference (t=5.37,P＜0.001).No significant tracer uptake occurred in other tissues and organs between the two groups (all t＜ 1.98,all P＞0.05).Conclusion The immunoactivity,characteristics of biodistribution and tumor targeting property of monoclonal antibody J591 show promising future and potential values in diagnosis and therapy of prostate cancer.